EXCEDRIN (MIGRAINE RELIEF) Drug Patent Profile

When do Excedrin (migraine Relief) patents expire, and when can generic versions of Excedrin (migraine Relief) launch?

Excedrin (migraine Relief) is a drug marketed by Haleon Us Holdings and is included in one NDA.

The generic ingredient in EXCEDRIN (MIGRAINE RELIEF) is acetaminophen; aspirin; caffeine. There are sixty-six drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the acetaminophen; aspirin; caffeine profile page.

Summary for EXCEDRIN (MIGRAINE RELIEF)

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	6
Clinical Trials:	1
DailyMed Link:	EXCEDRIN (MIGRAINE RELIEF) at DailyMed

Recent Clinical Trials for EXCEDRIN (MIGRAINE RELIEF)

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Albert Einstein Healthcare Network	Phase 4

See all EXCEDRIN (MIGRAINE RELIEF) clinical trials

Pharmacology for EXCEDRIN (MIGRAINE RELIEF)

Drug Class	Central Nervous System Stimulant Methylxanthine Nonsteroidal Anti-inflammatory Drug Platelet Aggregation Inhibitor
Mechanism of Action	Cyclooxygenase Inhibitors
Physiological Effect	Central Nervous System Stimulation Decreased Platelet Aggregation Decreased Prostaglandin Production

US Patents and Regulatory Information for EXCEDRIN (MIGRAINE RELIEF)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	EXCEDRIN (MIGRAINE RELIEF)	acetaminophen; aspirin; caffeine	TABLET;ORAL	020802-001	Jan 14, 1998		OTC	Yes	Yes

Expired US Patents for EXCEDRIN (MIGRAINE RELIEF)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	EXCEDRIN (MIGRAINE RELIEF)	acetaminophen; aspirin; caffeine	TABLET;ORAL	020802-001	Jan 14, 1998	4,943,565
Haleon Us Holdings	EXCEDRIN (MIGRAINE RELIEF)	acetaminophen; aspirin; caffeine	TABLET;ORAL	020802-001	Jan 14, 1998	5,972,916

International Patents for EXCEDRIN (MIGRAINE RELIEF)

See the table below for patents covering EXCEDRIN (MIGRAINE RELIEF) around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	565447
Canada	1288349	COMPRIME ANALGESIQUE D'ASPIRINE, ACETAMINOPHEN ET CAFEINE CONTENANT DE L'HYDROXYPROPYLCELLULOSE FAIBLEMENT SUBSTITUE (ANALGESIC TABLET OF ASPIRIN, ACETAMINOPHEN AND CAFFEINE CONTAININGLOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE)
Germany	69814636
Argentina	016337	USO DE UNA COMBINACION DE N-(4-HIDROXIFENIL)ACETAMIDA (ACETOAMINOFENOL,APAP); ACIDO 2-(ACETILOXI)BENZOICO (ASPIRINA ASA) Y 3,7-DIHIDRO-1, 3, 7-TRIMETIL-1H-PURINA-2,6-DIONA (CAFEINA, CAF) Y COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA COMBINACION

Market Dynamics and Financial Trajectory for EXCEDRIN (Migraine Relief)

Last updated: January 15, 2026

Summary

EXCEDRIN (Migraine Relief), a popular over-the-counter (OTC) medication, has sustained a notable presence in the analgesic segment. Its market dynamics are influenced by evolving consumer preferences, regulatory policies, and competitive pressures within OTC analgesics. This report delineates the pharmaceutical landscape, financial trends, competitive positioning, and future prospects for EXCEDRIN. Through comprehensive analysis, it aims to equip stakeholders with insights into its market trajectory, growth drivers, and associated risks.

---

What Are the Market Dynamics Shaping EXCEDRIN's Position?

Key Market Drivers

Driver	Details	Impact
Increasing Prevalence of Migraines	WHO estimates 15% of the global population suffers from migraines, translating to 1 billion people worldwide (2019).	Sustains demand for migraine-specific OTC products.
Consumer Preference for OTC Medications	Growing favorability for self-medication among consumers seeking quick, accessible relief.	Bolsters OTC analgesic market, including EXCEDRIN.
Expanded Distribution Channels	Growth in online pharmacy sales, convenience stores, and big-box retailers.	Accelerates product reach and availability.
Aging Population	Older demographics more prone to migraines and OTC medication usage.	Drives sustained demand within developed markets.
Increased Awareness & Education	Campaigns and health literacy initiatives improve product recognition.	Enhances consumer confidence and product loyalty.

Market Restraints and Challenges

Restraint	Details	Effect
Regulatory Scrutiny	FDA regulations tighten on combination OTC drugs, especially concerning dosage safety and ingredients.	Potentially limits formulation flexibility, impacting innovation.
Competition from Generic and Brand Variants	Coca-Cola’s brand “Goody’s Headache Powder,” CVS’s Comparable OTC options, and others compete directly.	Pressures market share and margins.
Consumer Shift Toward Natural Remedies	Increasing preference for herbal and alternative therapies.	Could reduce reliance on traditional OTC analgesics.
Ingredient Safety Concerns	Aspirin and caffeine-related side effects; risk of overuse leading to rebound headaches.	Necessitate marketing messaging and product adjustments.

Regulatory and Policy Environment

• FDA Oversight: The FDA classifies EXCEDRIN and similar products as OTC drugs requiring adherence to monographs [1].
• Labeling and Dosage Regulations: Recent focus on ingredient safety has led to stricter labeling, especially warnings about caffeine content to prevent overuse [2].
• Advertising Restrictions: Limitations on direct-to-consumer advertising for certain ingredients to ensure safe usage.

---

Financial Trajectory: Revenue, Market Share, and Growth Potential

Revenue Trends and Market Share

Year	Estimated Global Revenue (USD billions)	EXCEDRIN Market Share (%)	Notes
2018	2.9	~5	Stable, dominated by large OTC brands.
2019	3.1	~5.2	Slight growth driven by emerging markets.
2020	3.4	~5.5	Increased demand during pandemic; panic stockpiling.
2021	3.6	~6	Post-pandemic stabilization, marketing campaigns.
2022	3.8	~6.3	Continued growth, benefit from digital sales.

Note: Exact figures are estimates based on industry analyses and market reports.

Key Revenue Drivers

• Product Line Diversification: Introduction of formulations with targeted ingredients (e.g., caffeine-free variants).
• Geographic Expansion: Growing presence in emerging economies (e.g., India, Brazil).
• Brand Loyalty and Trust: Established brand equity supports repeat purchases.
• Advertising and Promotional Strategies: Targeted marketing campaigns amplify sales especially during migraine awareness months.

Profitability Outlook

Metric	2022 Estimate	Industry Benchmark	Notes
Gross Margin	45-50%	40-55%	Steady margins amidst raw material cost fluctuations.
Operating Margin	15-20%	10-20%	Efficient distribution and branding advantages.
Net Margin	10-15%	8-12%	Favorable for brand-driven OTC product.

Future Growth Potential

Factor	Potential Impact	Estimated Compound Annual Growth Rate (CAGR) (2023-2028)
Market Expansion	Broader geographic footprint	3-4%
Product Innovation	New formulations, combination therapies	2-3%
Digital & E-commerce	Enhanced direct-to-consumer sales	4-5%
Regulatory Favorability	Streamlined approval processes	+1-2%

Overall, the OTC analgesics segment, with EXCEDRIN as a key player, projects a CAGR of approximately 3-4% over the next five years, driven by expanding global markets and product innovation.

---

How Does EXCEDRIN Compete with Alternatives?

Competitive Landscape Overview

Competitors	Market Share (%)	Key Differentiators	Price Range (USD)	Distribution Channels
EXCEDRIN	6.3	Brand recognition, combination of analgesics	5-7	Pharmacies, online, drugstores
Goody’s Headache Powder	4	Older familiar brand, cost-effective	4-6	Convenience stores, pharmacies
Tylenol Extra Strength	10	Personal health brand, single-ingredient focus	6-8	Broad retail presence
Ibuprofen brands (Advil, Motrin)	12	Anti-inflammatory properties	7-9	Global retail networks

Product Positioning

• EXCEDRIN: Focuses on fast relief for migraines with combination analgesics (acetaminophen, aspirin, caffeine).
• Competitors: Varying focus—single-ingredient, herbal, or anti-inflammatory options.

Strategies for Future Competitive Advantage

Strategy	Details
Product Differentiation	Innovation with caffeine-free or natural variants.
Digital Engagement	Enhanced online marketing, telemedicine collaborations.
Formulation Safety	Emphasize ingredient safety, proper dosage alerts.
Market Penetration	Expand reach in emerging markets via e-commerce & local partnerships.

---

What Are the Future Outlooks and Risks?

Opportunities

• Growing Demand for Self-care: Increased consumer empowerment favors OTC brands.
• Technological Integration: Use of data analytics and AI for targeted marketing.
• Regulatory Favorability: Potential simplification for certain formulations.

Risks

Risk	Impact	Mitigation Strategies
Regulatory Restrictions	Could limit ingredient use	Ongoing compliance, innovation in formulations.
Market Saturation	Competition erodes margins	Brand differentiation, diversification.
Ingredient Safety Concerns	Safety scares can damage reputation	Transparency, safety studies.
Supply Chain Disruption	Raw material shortages	Diversify suppliers, inventory buffering.

---

Conclusion and Recommendations

EXCEDRIN occupies a resilient position within the OTC analgesic market, bolstered by consumer familiarity and strategic distribution. Its financial trajectory indicates steady growth, bolstered by geographic expansion, product innovation, and digital commerce. Stakeholders should prioritize:

• Investing in R&D for formulation diversification.
• Strengthening digital and e-commerce channels.
• Monitoring regulatory developments closely.
• Emphasizing safety profiles to mitigate public health concerns.

Long-term growth hinges on balancing innovation, compliance, and consumer engagement within an increasingly competitive landscape.

---

Key Takeaways

• The OTC migraine relief market, with EXCEDRIN as a prominent player, is projected to grow at approximately 3-4% CAGR over the next five years.
• Consumer preferences are shifting toward natural remedies and digital channels, influencing product development and distribution strategies.
• Regulatory scrutiny around safety and ingredient labeling offers both challenges and opportunities for innovation.
• Financially, EXCEDRIN benefits from brand loyalty, product diversification, and expanding markets, maintaining margins comparable to industry averages.
• Competitive differentiation relies on formulation innovation, digital engagement, and safety transparency.

---

FAQs

1. What distinguishes EXCEDRIN from other OTC migraine remedies?
   EXCEDRIN uniquely combines acetaminophen, aspirin, and caffeine to deliver rapid relief, leveraging a trusted brand and proven formulation, though competitors offer single-ingredient or herbal alternatives.

2. How are regulatory changes impacting EXCEDRIN’s market?
   Stricter FDA guidelines on ingredient safety and labeling, especially regarding caffeine content, compel product reformulation, clear labeling, and compliance to sustain market presence.

3. What growth strategies should EXCEDRIN adopt?
   Focus on product innovation (e.g., caffeine-free options), expanding into emerging markets via digital channels, and enhancing consumer education to foster brand loyalty.

4. What risks threaten EXCEDRIN’s market share?
   Increased competition, regulatory shifts, consumer preference for natural products, and potential safety concerns are primary risks requiring proactive management.

5. Is the OTC migraine relief segment saturated?
   While mature in developed markets, substantial growth remains in emerging economies. Continuous innovation and digital penetration are key to capturing additional market share.

---

References

[1] U.S. Food & Drug Administration. (2022). OTC Drug Review.
[2] FDA Labeling Guidelines for OTC Drugs. (2021).
[3] World Health Organization. (2019). Headache disorders.
[4] MarketWatch. (2022). OTC Analgesics Market Size, Share & Trends.
[5] IBISWorld. (2022). Over-the-Counter (OTC) Medication Industry Reports.